Disopyramide Phosphate

CHEMBL1201020 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
437.5 g/mol
LogP
Phase
4

The phosphate salt form of disopyramide, used in oral and injectable preparations for the treatment of ventricular and supraventricular arrhythmias. Like the parent compound, it blocks cardiac sodium channels and has prominent anticholinergic side effects. Therapeutic drug monitoring is sometimes used to optimize dosing.

น้ำหนักโมเลกุล

437.5000 g/mol

TPSA

137.00 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C.O=P(O)(O)O

InChI

InChI=1S/C21H29N3O.H3O4P/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19;1-5(2,3)4/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25);(H3,1,2,3,4)

Molecular Formula

C21H32N3O5P

HBD / HBA

4 / 7

พันธะที่หมุนได้

8

อะตอมหนัก

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The phosphate salt form of disopyramide, used in oral and injectable preparations for the treatment of ventricular and supraventricular arrhythmias. Like the parent compound, it blocks cardiac sodium channels and has prominent anticholinergic side effects. Therapeutic drug monitoring is sometimes used to optimize dosing.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Disopyramide Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201020. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 30928. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.